Apogee Therapeutics falls after eczema drug shows lower response rate than rival treatments

Shares of drug developer Apogee Therapeutics APGE.O fall 17.9% to $38.97

On a scoring system called IGA0/1, which assesses the severity of the disease, company's experimental drug showed a 34.9% response rate

This compared to 38% seen with Eli Lilly's LLY.N Ebglyss and 37% from Sanofi SASY.PA and Regeneron Pharmaceuticals' REGN.O Dupixent

APGE is studying its drug APG777 to treat patients with moderate-to-severe atopic dermatitis, a chronic disease that causes inflammation, redness and irritation of skin

"The stock weakness post-data is curious and possibly explained by slightly discordant but still statistically significant IGA results that look in line with Dupixent/Ebglyss" - BTIG

Company says APG777 showed a high response rate with a 71% reduction in eczema severity, compared with placebo of 33.8%, at week 16 in Part A of the mid-stage study

Expects to share the 280-patient study data from Part B in mid-2026

Including session moves, stock down 13.1% YTD